Compare IDEXX Laboratories, Inc. (IDXX) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Pfizer Inc — how do they compare? IDEXX Laboratories, Inc. trades at $560 (market cap $44.48B), while Pfizer Inc trades at $24.8 (market cap $141.06B). The key difference: Pfizer Inc is far larger — about 3.2× IDEXX Laboratories, Inc.'s market cap, and Pfizer Inc pays a 6.95% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | PFE | |
|---|---|---|
Market Cap | $44.48B | $141.06B |
Sector | Health | Health |
52-Week High | $766.68 | $28.56 |
52-Week Low | $520.87 | $23.29 |
Enterprise Value | $45.38B | $191.72B |
Volume | — | 29,869,932 |
Dividend Yield | — | 6.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a bullish technical signal despite near-term resistance. The company maintains solid fundamentals with a P/E of 19.12, net income margin of 11.83%, and consistent quarterly earnings beats. Recent news highlights pipeline advancements in oncology and obesity treatments, positioning for a catalyst-rich 2026.
The outlook is cautiously optimistic, supported by a $28.25 analyst price target and a 38.46% buy rating. Key opportunities include dividend stability and pipeline progress, while risks involve patent cliffs and revenue normalization post-COVID. The stock presents a value proposition for income-focused investors amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
